Imaging modalities for the noninvasive assessment of fibrosis in Crohn&apos;s disease. by Stasi, C. et al.
The Scientific World Journal
Volume 2012, Article ID 450151, 7 pages
doi:10.1100/2012/450151
The cientificWorldJOURNAL
Review Article
Imaging Modalities for the Noninvasive Assessment of
Fibrosis in Crohn’s Disease
Cristina Stasi,1 Massimo Falchini,2 and Stefano Milani2
1Department of Internal Medicine, University of Florence, 50134 Florence, Italy
2Department of Clinical Pathophysiology, University of Florence, 50139 Florence, Italy
Correspondence should be addressed to Cristina Stasi, cristina.stasi@unifi.it
Received 30 October 2011; Accepted 3 January 2012
Academic Editor: Fabio Fornari
Copyright © 2012 Cristina Stasi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The development of strictures in Crohn’s disease is a main cause of hospitalization and often represent an indication for
surgery. The differentiation between inflammatory and fibrotic strictures is useful to determine the optimal treatment. Today, the
availability of noninvasive methods to assess the presence and extension of strictures offers new tools for the diagnosis and follow-
up of the disease. Bowel ultrasound, power doppler ultrasound, contrast-enhanced ultrasound, magnetic resonance imaging offer
the additional advantage that they do not expose patients to ionizing radiation. In this paper we provide an update on the accuracy
of these noninvasive methods for the diagnosis of Crohn’s disease.
1. Introduction
The incidence of Crohn’s disease (CD) is increasing world-
wide. The highest incidences have been reported in northern
Europe, the United Kingdom, and North America. In the
past 50 years, the incidence and prevalence in the West has
increased up to 6–15/100,000 and 50–200/100,000 persons,
respectively [1].
CD is a chronic inflammatory condition of the gastroin-
testinal tract, in which genetic, psychological, immune, and
inflammatory factors have been suggested to play a role in its
pathogenesis [2].
The physiological immune response in the gut to sup-
press a possible over reactivity bowel antigens or antigens
introduced by food. Pizarro et al. [3] suggest that local
TNF production by intestinal epitelial cell may be key in
maintaining proper innate immune defences. Early dete-
rioration of its expression can lead to increased bacterial
penetration and exposure of underlying mucosal immune
cells to commensal antigens, thus triggering the onset of in-
testinal inflammation.
The transmural fibrogenic process observed in CD is
believed to be induced by a complex interplay between
inflammatory and fibrogenic cells. As for other diseases
characterized by fibrosis, myofibroblasts have been suggested
to play a key role in intestinal fibrosis. However, most of the
assumptions on the pathophysiology of fibrosis in CD are
based on data analyzing the fibrogenic process occurring in
other organs.
Strictures are often responsible of patient’s hospitaliza-
tions and surgeries [4]. Histologically, strictures contain
a mixture of inflammatory and mesenchymal cells with
deposition of an excess of extracellular matrix, resulting in
different degrees of fibrosis [5]. In fact, strictures may be
predominantly inflammatory or fibrotic, causing diagnostic
and therapeutic uncertainty. Treatment regimens include
immune modulators, but this therapy fails when there is
intestinal fibrosis [6]. This would require clinical assessment
with noninvasive methods to determine the activity and
extent of disease and to assess intestinal fibrosis.
Bowel ultrasound is useful to detect intestinal and
extraintestinal lesions, including bowel wall thickening,
stenosis with or without bowel dilation, and the presence
of abscesses and fistulae. Contrast-enhanced ultrasound
(CEUS) may show an enhancement of the bowel wall signal
associated with disease activity. In particular, in patients
with stenotic segments and incomplete bowel obstruction,
it is very important to distinguish between fibrosis and
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inflammation (enhancement with CEUS). These diagnostic
techniques do not expose patients to ionizing radiation haz-
ards and may be repeated frequently during the monitoring
of therapy, particularly to exclude the need for surgery.
Magnetic resonance imaging (MRI) has also been pro-
posed as a useful tool to distinguish between intestinal
inflammation and fibrosis. Similarly to bowel ultrasound,
it does not expose to ionizing radiation, but its costs and
accessibility might preclude its frequent use in the mon-
itoring of patients. On the other hand, one of the main
advantages of MRI is that it provides more detailed informa-
tion about disease involvement of the small bowel wall and
possible extraintestinal complications [7].
This paper provides an update of non-invasive diagnosis
of Crohn’s disease, focusing on the role of transabdominal
ultrasound and magnetic resonance in the detection of
intestinal fibrosis in Crohn’s disease. The aim is to discuss the
accuracy of abdominal ultrasound and magnetic resonance
in Crohn’s disease in order to establish a proper diagnostic
assessment and optimize treatment.
2. Assessment by Transabdominal Ultrasound
Improvements in technology and increasing experience
with ultrasound in inflammatory bowel disease (IBD)
have confirmed the role of ultrasound as a clinical tool
in Gastroenterology Units. Transabdominal ultrasound is
clinically useful as a non-invasive imaging modality in the
diagnosis of IBD by evaluating bowel wall thickness, peri-
intestinal inflammatory reaction, and by estimating extralu-
minal complications such as stenosis, fistula, and abscesses.
For these reasons, transabdominal ultrasound has been
proposed as a first-line diagnostic tool in assessing patients
with Crohn’s disease regardless of their clinical symptoms
and/or disease activity [7, 8]. In recent studies, sensitivity
of transabdominal ultrasound in detecting Crohn’s disease
ranges from 84 to 93% when compared with endoscopy
and/or radiology as gold standard [9–11]. Specificity is 98%,
in the study of Astegiano and coworkers [9] performed on
313 consecutive outpatients presenting with abdominal pain
and irregular bowel habits lasting more than 3 months. It
has been suggested that disease location is the main factor
influencing the accuracy of ultrasound for the diagnosis of
CD. Sensitivity is lower for less accessible locations such as
rectum (14.2%) and upper small bowel (28.6%) [10].
The initial diagnosis of CD may be supported by ultra-
sound measurement of bowel wall thickness. Most studies
reported normal wall thickness ranging from 1 up to 4mm
[12]. As shown in Figure 1, the ileum wall echotexture (high-
resolution transducers usually permit visualization of five
layers) and the possible involvement of contiguous structures
could also be informative and should be considered [8].
In particular, a correlation has been found between wall
thickness and disease activity. Wall thickness is significantly
higher in active (Crohns Disease Activity Index, CDAI >
150) than in inactive disease (CDAI< 150). Moreover an
association between fibrosis and wall thickening was found.
This association is important for differential diagnosis of
inflammatory and fibrotic bowel wall changes. Fibrotic
stenoses are mostly represented in segments with wall thick-
ening <20–30mm, whereas inflammatory lesions are more
frequent in segments with >30mm wall thickening [8]. The
addition of an oral nonadsorbable solution (polyethylene
glycol) results in an increase in the sensitivity of ultrasound
in defining anatomic location and extension of segments
with active disease [13, 14].
3. Assessment by Power Doppler and
Contrast-Enhanced Ultrasound
Newer techniques such as power Doppler and the admin-
istration of echo-enhancing agents have further improved
sensitivity and accuracy.
A strong correlation between colour Doppler sono-
graphic vascularity and colonoscopy and histology of the
terminal ileum and the right colon was found [15, 16].
These studies suggest the utility of power Doppler
ultrasound in the assessment of changes of the bowel wall
determined by pharmaceutical treatment.
In patients with CD, the analysis of vascularity after
intravenous injection of Levovist increases the accuracy of
transabdominal ultrasound and may facilitate the differen-
tiation between inflammatory and fibrotic stenosis [17, 18].
Other studies [19, 20] employing second-generation
intravenous contrast agent (SonoVue) reported similar re-
sults in the accuracy of CEUS.
Different diffusion-perfusion patterns of bowel wall
enhancement can be observed in CD [19, 20], reflecting
different degrees of disease activity: submucosal prevalent
enhancement, transparietal enhancement starting from the
submucosa, and transparietal enhancement pattern starting
from extravisceral vessels and involving the whole wall
with an external-to-internal direction. These patterns may
represent the basis for a semiquantitative method to assess
wall vascularisation. Serra et al. [19] described a quantitative
method based on the E/W ratio, in which E is the major
thickness of the enhanced layer, and W is the thickness of
the entire wall section.
CEUS is a sensitive tool for the determination of disease
activity and it was seen to be useful in the followup of treat-
ment. In addition, this technique has been helpful in surgical
management, particularly in the decision of conservative
versus surgical treatment [21, 22]. In fact, hypervascularity
of stenosed segments was shown in intestinal obstruction
subsequent to inflammatory cause, while hypovascularity
was found in cicatricial stenosis [23].
In a recent study [24] intestinal fibrosis was evaluated
by measuring strain (degree of compression of a material in
response to a force applied to a fixed area), that is developed
in the tissue. In the study, 7 consecutive patients with ste-
nosed segment were studied with ultrasound elasticity imag-
ing. Their stenotic and normal bowel segments were evalu-
ated by ex vivo elastometry and histopathology after surgical
resection. In addition, female Lewis rats undergoing weekly
trinitrobenzene (5 with subsequent acute inflammatory
colitis and 6 with chronic intestinal fibrosis) were evaluated.
The study showed that ultrasound elasticity imaging can
The Scientific World Journal 3
(a) (b)
Figure 1: (a) Thickening of the ileum wall (6.4mm). Maintained laminar aspect of the intestinal wall and (b) enlarged lymph node (white
circle) near the terminal ileum.
differentiate inflammatory from intestinal fibrosis in rat
models, as well as fibrotic lesions from unaffected intestine
in patients with CD.
Ultrasound elasticity imaging could identify the patients
with high risk to develop fibrosis and rapidly progress
to fibrostenotic strictures. Therefore, it could be useful in
treatment decision, but future prospective clinical studies are
needed.
4. Assessment by Magnetic Resonance Imaging
MRI provides information about complications and extrain-
testinal manifestations, without exposure to ionizing radia-
tion. The major advantage of MRI over US is the assessment
of the entire gastrointestinal tract [25]. On the contrary, the
disadvantages are the accessibility to this imaging modalities,
greater cost, longer interpretation time and duration of the
exam, contraindication such as claustrophobia, pacemaker,
ferromagnetic vascular clips, ferromagnetic foreign body in
the noble (intracranial, intraocular or vascular), Swan-Ganz
catheter.
MRI is able to provide a rapid and accurate evaluation
of the abdomen and pelvis. In particular, it can be helpful
in providing an evaluation of the activity of perianal CD
[26]. It assesses the features of an altered bowel segment
through characteristic patterns of attenuation and degrees of
enhancement.
Some technical aspects, in particular the distension of
the bowel, enhance the accuracy of MRI. For this reason a
large amount of oral contrast is used in MRI examination.
Oral contrast also decreases the susceptibility to artifacts
by displacing intraluminal air. Positive contrast agents,
represented by paramagnetic substances such as gadolinium
chelates, increase intraluminal signal (hyperintense on both
T1-weighted and T2-weighted). On the contrary, negative
contrast agents reduce intraluminal signal. Moreover, they
improve the visualization of inflamed bowel wall and
surrounding fat on T2 images [27]. Bowel wall thickening is
detected on T2 images and bowel wall enhancement is better
appreciated on T1 images. Fat saturation may be used to
increase contrast resolution. This technical aspect also allows
a better assessment of bowel enhancement [28, 29].
Bowel wall thickness can be scored as normal (< 3mm),
mildly abnormal (3–6mm), ormarkedly abnormal (> 6mm)
[30]. The changes characteristically associated with disease
activity are the increase of wall thickness and the enhance-
ment after injection ofMRI contrast and presence of oedema.
Borthne et al. [11] compared ultrasound and MRI
using ileocolonoscopy as reference standard in 53 paediatric
patients with suspected IBD. Ultrasound showed higher
sensitivity than MRI (93% versus 82%), but only the
terminal ileum, the location with the highest accuracy for
ultrasound, was examined. In a tertiary care medical center,
120 patients with diagnosis of CD or subjects who were
suspected of having CD underwent MR enterography. MR
enterography demonstrated active CD in 57% of patients,
chronic changes of CD without active inflammation (e.g.,
stricture, fistula, or abscess) in 12.5% of cases. The authors
demonstrated that MR Enterography can add significant
information to the clinical evaluation of these patients and
were useful to determine if new surgical or medical treatment
was required [31]. Figure 2 shows the relapse of disease after
resection and primary anastomosis.
In another tertiary medical center, a study on 213
patients during 4-year showed that 60% ofMR Enterography
presented bowel wall thickening and 53% displayed a clear
signal enhancement [32].
Several studies [33–37] have evaluated the accuracy of
MRI in the assessment of activity in the terminal ileum
and/or the colon, showing that a higher accuracy for the
assessment of disease activity can be obtained using luminal
negative contrast.
Del Vescovo et al. [33] studied 16 CD patients who
underwent ileocolonoscopy with biopsy and MRI. The
authors observed a strong correlation between MRI and
histological findings. Bowel segments with active disease
presented a layered pattern of enhancement, while inactive
disease presented homogeneous contrast uptake. In active
disease, during intravascular phase of contrast distribution,
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Figure 2: (a) MR enterography, T2 weighted sequence (HASTE, half-Fourier axial single-shot fast spin-echo): relapse of segmental disease
associated with segmental wall thickening at the site of previous ileocolic anastomosis; (b) MR enterography T2 weighted sequence
(TrueFISP, true fast imaging with steady-state free precession) delineated profiles of segmental wall thickening and mild comb sign; (c-d) MR
enterography, T1-weighted sequence (VIBE, volumetric interpolated breath-hold examination): postcontrast homogeneous enhancement
of the intestinal wall suggesting a fibrotic lesion.
the authors showed the predominance of vasodilatation
over neoangiogenesis with a fast rise of the mucosa-
submucosa (internal layers) enhancement curve. On the
contrary, muscularis-serosa (external layers) enhancement
curve showed a “slower and lower” trend. In inactive disease,
the predominance of neoangiogenesis over vasodilatation,
probably due to parietal repair of the chronic damage,
resulted in similar trends of the mucosa-submucosa and
muscularis-serosa curves in all phases. The absence of
the enhancement curves between the two layers mucosa-
submucosa and muscularis-serosa in intravascular distri-
bution of contrast agent was likely due to the absence of
vasodilatation.
In Figure 3 the active inflammation in CD manifests as
high signal intensity into the bowel wall.
Several studies confirm the possibility to distinguish the
active inflammation from the chronic changes of fibrosis
based on different enhancement patterns [5, 34, 35].
Figure 4 shows a chronic fibrotic stricture, in which there
is homogeneous contrast enhancement without evidence of
oedema or hyperaemia.
The study of Lasocki and colleagues [34], performed
retrospectively in 26 patients with recent histology (surgery
and/or colonoscopy), showed that MRI is most sensitive
to detect active CD. Moreover, the most sensitive signs
were those related to the bowel wall, namely, thickening,
nodularity, contrast enhancement, and oedema. In the study
of Ha et al. [35] 119 patients with obstructive symptoms
were enrolled. Fifty-five % of patients required escalation
of medical therapy and 32.5% were directed to surgery. All
MR Enterography studies were performed in fasted patients
followed by oral ingestion of a sorbitol-based biphasic
contrast and it was given immediately prior to scanning the
noncontrast sequences. A single dose of gadolinium contrast
agent was administered before the postcontrast sequences.
The presence of early postcontrast bowel wall enhancement
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Figure 3: Active inflammation in Crohn’s disease: (a) T2W sequence (HASTE): homogeneous wall thickening with intramural focal
hyperintense signal area compliant with active inflammation; (b) postcontrast T1W sequence (VIBE) showing mucosal enhancement with
laminar appearance of the wall (with arrows).
(a) (b)
Figure 4: (a) HASTE sequence: mild inflammatory activity; distal ileum involved by disease with inhomogeneous wall thickening (white
circle) (b) T1-weighted sequence (VIBE): postcontrast homogenous wall enhancement compliant with fibrotic evolution and reduced
inflammatory activity (white arrows).
and thickening in the setting of intermediate to increased
T2 signal intensity bowel wall thickening was classified as
active inflammation. The presence of fibrosis was suggested
by delayed or absent contrast.
In the study of Lawrence et al. [36] response to continued
medical therapy after MRI was prospectively assessed at
8-wk. Nonresponders underwent endoscopy. In patients
undergoing surgical resection, the correlation between sur-
gical pathology and the MRI was assessed, confirming the
accuracy of MRI in the classification of both inflammation
severity and the presence of fibrosis.
A recent study [5] was conducted to determine the utility
of magnetization transfer (MT) MRI in the identification
and quantification of intestinal fibrosis in a rat model of
CD. Magnetization transfer MRI shows different molecular
properties with respect to MRI. MT generates contrast that
is primarily determined by the fraction of large macro-
molecules or immobilized phospholipids cell membranes in
tissue. MT is able to determine the fibrotic content of small
bowel strictures. Fibrosis progression was inducted in Lewis
rats injected subserosally with peptidoglycan-polysaccharide.
They develop bowel inflammation 1 day after laparotomy
and fibrosis starting 14 days after laparotomy. The authors
performed MRI in 25 rats injected with peptidoglycan-
polysaccharide and 13 injected with human serum albumin
(control animals). They showed that magnetization transfer
can help detect fibrosis and that magnetization transfer ratio
correlates with tissue collagen and it is sensitive to monitor
changes in fibrosis progression into the natural history of CD.
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5. Conclusions
Bowel ultrasound should be the first-line diagnostic modal-
ity for disease assessment and follow-up examinations with
high accuracy. Ultrasound and MRI can be used in clinical
practice as imaging modalities for assessment of fibrosis in
the terminal ileum and colon. CEUS may be particularly
useful in the followup of patients with CD and for the
assessment of the efficacy of medical therapy in reducing
bowel wall vascularity.
Abbreviations
CD: Crohn’s disease
CEUS: Contrast-enhanced ultrasound
MRI: Magnetic resonance imaging
IBD: Inflammatory bowel disease
CDAI: Crohn’s disease activity index
MT: Magnetization transfer.
References
[1] J. Cosnes, C. Gower-Rousseau, P. Seksik, and A. Cortot, “Epi-
demiology and natural history of inflammatory bowel dis-
eases,” Gastroenterology, vol. 140, no. 6, pp. 1785–1794, 2011.
[2] S. Ardizzone and G. Bianchi Porro, “Inflammatory bowel
disease: new insights into pathogenesis and treatment,” Journal
of Internal Medicine, vol. 252, no. 6, pp. 475–496, 2002.
[3] T. T. Pizarro, L. Pastorelli, G. Bamias et al., “SAMP1/YitFc
mouse strain: a spontaneous model of Crohn’s disease-like
ileitis,” Inflammatory Bowel Diseases, vol. 17, no. 12, pp. 2566–
2584, 2011.
[4] L. Peyrin-Biroulet, E. V. Loftus, J. F. Colombel, and W. J.
Sandborn, “The natural history of adult crohn’s disease in
population-based cohorts,” American Journal of Gastroenterol-
ogy, vol. 105, no. 2, pp. 289–297, 2010.
[5] J. Adler, S. D. Swanson, P. Schmiedlin-Ren et al., “Magnetiza-
tion transfer helps detect intestinal fibrosis in an animal model
of Crohn disease,” Radiology, vol. 259, no. 1, pp. 127–135,
2011.
[6] M. H. Holtmann and M. F. Neurath, “Anti-TNF strategies
in stenosing and fistulizing Crohn’s disease,” International
Journal of Colorectal Disease, vol. 20, no. 1, pp. 1–8, 2005.
[7] S. B. Hanauer, “Bowel ultrasound for the assessment of
Crohn’s disease,” Gastroenterol Hepatol, vol. 7, no. 2, pp. 107–
109, 2011.
[8] C. F. Dietrich, “Significance of abdominal ultrasound in in-
flammatory bowel disease,” Digestive Diseases, vol. 27, no. 4,
pp. 482–493, 2009.
[9] M. Astegiano, F. Bresso, T. Cammarota et al., “Abdominal
pain and bowel dysfunction: diagnostic role of intestinal ultra-
sound,” European Journal of Gastroenterology and Hepatology,
vol. 13, no. 8, pp. 927–931, 2001.
[10] F. Parente, S. Greco, M. Molteni et al., “Role of early
ultrasound in detecting inflammatory intestinal disorders
and identifying their anatomical location within the bowel,”
Alimentary Pharmacology and Therapeutics, vol. 18, no. 10, pp.
1009–1016, 2003.
[11] A. S. Borthne, M. Abdelnoor, J. Rugtveit, G. Perminow, T.
Reiseter, and N. E. Kløw, “Bowel magnetic resonance imaging
of pediatric patients with oral mannitol: MRI compared to
endoscopy and intestinal ultrasound,” European Radiology,
vol. 16, no. 1, pp. 207–214, 2006.
[12] J. Pane´s, R. Bouzas, M. Chaparro et al., “Systematic review: the
use of ultrasonography, computed tomography and magnetic
resonance imaging for the diagnosis, assessment of activity
and abdominal complications of Crohn’s disease,” Alimentary
Pharmacology and Therapeutics, vol. 34, no. 2, pp. 125–145,
2011.
[13] F. Parente, S. Greco, M.Molteni et al., “Oral contrast enhanced
bowel ultrasonography in the assessment of small intestine
Crohn’s disease. A prospective comparison with conventional
ultrasound, x ray studies, and ileocolonoscopy,” Gut, vol. 53,
no. 11, pp. 1652–1657, 2004.
[14] F. Castiglione, L. Bucci, G. Pesce et al., “Oral contrast-
enhanced sonography for the diagnosis and grading of post-
surgical recurrence of Crohn’s disease,” Inflammatory Bowel
Diseases, vol. 14, no. 9, pp. 1240–1245, 2008.
[15] M. Epifanio, M. Baldisserotto, J. V. Spolidoro, and A. Gaiger,
“Grey-scale and colour Doppler sonography in the evaluation
of children with suspected bowel inflammation: correlation
with colonoscopy and histological findings,” Clinical Radiol-
ogy, vol. 63, no. 9, pp. 968–978, 2008.
[16] B. H. Drews, T. F. E. Barth, M. M. Ha¨nle et al., “Comparison
of sonographically measured bowel wall vascularity, histology,
and disease activity in Crohn’s disease,” European Radiology,
vol. 19, no. 6, pp. 1379–1386, 2009.
[17] A. di Sabatino, I. Fulle, R. Ciccocioppo et al., “Doppler en-
hancement after intravenous Levovist injection in Crohn’s
disease,” Inflammatory Bowel Diseases, vol. 8, no. 4, pp. 251–
257, 2002.
[18] G. L. Rapaccini, M. Pompili, R. Orefice et al., “Contrast-
Enhanced Power Doppler of the Intestinal Wall in the
Evaluation of Patients with Crohn Disease,” Scandinavian
Journal of Gastroenterology, vol. 39, no. 2, pp. 188–194, 2004.
[19] C. Serra, G. Menozzi, A. M. M. Labate et al., “Ultrasound
assessment of vascularization of the thickened terminal ileum
wall in Crohn’s disease patients using a low-mechanical
index real-time scanning technique with a second generation
ultrasound contrast agent,” European Journal of Radiology, vol.
62, no. 1, pp. 114–121, 2007.
[20] V. Migaleddu, A. M. Scanu, E. Quaia et al., “Contrast-
Enhanced Ultrasonographic Evaluation of Inflammatory
Activity in Crohn’s Disease,” Gastroenterology, vol. 137, no. 1,
pp. 43–52, 2009.
[21] K. Kunihiro, J. Hata, N. Manabe et al., “Predicting the
need for surgery in Crohn’s disease with contrast harmonic
ultrasound,” Scandinavian Journal of Gastroenterology, vol. 42,
no. 5, pp. 577–585, 2007.
[22] G. Maconi, G. M. Sampietro, A. Sartani, and G. Bianchi Porro,
“Bowel ultrasound in Crohn’s disease: surgical perspective,”
International Journal of Colorectal Disease, vol. 23, no. 4, pp.
339–347, 2008.
[23] W. Kratzer, C. von Tirpitz, R. Mason et al., “Contrast-
enhanced power Doppler sonography of the intestinal wall in
the differentiation of hypervascularized and hypovascularized
intestinal obstructions in patients with Crohn’s disease,”
Journal of Ultrasound in Medicine, vol. 21, no. 2, pp. 149–157,
2002.
[24] R. W. Stidham, J. Xu, L. A. Johnson et al., “Ultrasound elastic-
ity imaging for detecting intestinal fibrosis and inflammation
in rats and human’s with Crohn’s disease,” Gastroenterology,
vol. 141, no. 3, pp. 819–826.e1, 2011.
The Scientific World Journal 7
[25] R. Sinha, P. Murphy, P. Hawker, S. Sanders, A. Rajesh, and R.
Verma, “Role of MRI in Crohn’s disease,” Clinical Radiology,
vol. 64, no. 4, pp. 341–352, 2009.
[26] C. Villa, G. Pompili, G. Franceschelli et al., “Role of magnetic
resonance imaging in evaluation of the activity of perianal
Crohn’s disease,” European Journal of Radiology, vol. 81, no.
4, pp. 616–622, 2012.
[27] A. Kayhan, J. Oommen, F. Dahi, and A. Oto, “Magnetic reso-
nance enterography in Crohn’s disease: standard and advanced
techniques,” World Journal of Radiology, vol. 2, no. 4, pp. 113–
121, 2010.
[28] T. C. Lauenstein, H. Schneemann, F. M. Vogt, C. U. Herborn,
S. G. Ru¨hm, and J. F. Debatin, “Optimization of oral contrast
agents forMR imaging of the small bowel,”Radiology, vol. 228,
no. 1, pp. 279–283, 2003.
[29] N. Gourtsoyiannis, N. Papanikolaou, J. Grammatikakis, T.
Maris, and P. Prassopoulos, “MR enteroclysis protocol opti-
mization: comparison between 3D FLASH with fat satura-
tion after intravenous gadolinium injection and true FISP
sequences,” European Radiology, vol. 11, no. 6, pp. 908–913,
2001.
[30] O. A. Kamal and M. M. Shabrawy, “Prognostic role of MRI
in determining small bowel Crhon’s disease categories: corre-
lation with response to medical therapy,” Egyptian Journal of
Radiology and Nuclear Medicine, vol. 42, no. 3-4, pp. 335–342,
2011.
[31] E. Messaris, N. Chandolias, D. Grand, and V. Pricolo, “Role
of magnetic resonance enterography in the management of
Crohn disease,” Archives of Surgery, vol. 145, no. 5, pp. 471–
475, 2010.
[32] S. Shrot, E. Konen, M. Hertz, and M. Amitai, “Magnetic res-
onance enterography: 4 years experience in a tertiary medical
center,” Israel Medical Association Journal, vol. 13, no. 3, pp.
172–176, 2011.
[33] R. del Vescovo, I. Sansoni, R. Caviglia et al., “Dynamic contrast
enhanced magnetic resonance imaging of the terminal ileum:
differentiation of activity of Crohn’s disease,” Abdominal
Imaging, vol. 33, no. 4, pp. 417–424, 2008.
[34] A. Lasocki, A. Pitman, R. Williams, B. Lui, A. V. Kalade, and S.
Farish, “Relative efficacy of different MRI signs in diagnosing
active Crohn’s disease, compared against a histological gold
standard,” Journal of Medical Imaging and Radiation Oncology,
vol. 55, no. 1, pp. 11–19, 2011.
[35] C. Y. Ha, N. Kumar, C. A. Raptis, V. R. Narra, and M. A.
Ciorba, “Magnetic resonance enterography: safe and effective
imaging for stricturing Crohn’s disease,” Digestive Diseases and
Sciences, vol. 56, no. 10, pp. 2906–2913, 2011.
[36] I. C. Lawrance, C. J. Welman, P. Shipman, and K. Murray,
“Correlation of MRI-determined small bowel Crohn’s disease
categories with medical response and surgical pathology,”
World Journal of Gastroenterology, vol. 15, no. 27, pp. 3367–
3375, 2009.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
